Related Experiment Videos
Hypertriglyceridemia and low HDL: therapeutic considerations
1Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health Sciences University, Portland, Oregon, USA.
Current Opinion in Lipidology
|February 1, 1994
Summary
New guidelines highlight triglycerides and HDL cholesterol in heart disease risk. This review covers treatment strategies for high triglycerides or low HDL cholesterol, examining triglyceride-lowering drugs and their effects on lipoproteins.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Pharmacology
Background:
- Recent European and US guidelines emphasize triglycerides and HDL cholesterol as key risk factors for coronary heart disease.
- Dyslipidemia, characterized by abnormal lipid levels, remains a significant concern in cardiovascular risk assessment.
Purpose of the Study:
- To review therapeutic considerations for managing hypertriglyceridemia and low HDL cholesterol in light of updated guidelines.
- To evaluate the impact of triglyceride-lowering drugs on lipoprotein concentrations and metabolism in dyslipidemic patients.
Main Methods:
- Literature review of recent guidelines and clinical studies.
- Analysis of pharmacological interventions targeting triglyceride and HDL cholesterol levels.
- Evaluation of studies assessing the effects of triglyceride-lowering agents on lipoprotein profiles.
Main Results:
- Updated guidelines underscore the importance of addressing triglyceride and HDL cholesterol levels for coronary heart disease prevention.
- Triglyceride-lowering drugs demonstrate varying effects on lipoprotein metabolism, influencing overall lipid profiles.
- Therapeutic strategies need to be tailored considering individual patient lipid abnormalities and cardiovascular risk.
Conclusions:
- Management of hypertriglyceridemia and low HDL cholesterol is crucial for cardiovascular risk reduction.
- Triglyceride-lowering medications play a role in modifying lipoprotein metabolism, but their clinical impact requires careful consideration.
- Personalized therapeutic approaches are essential for optimizing lipid management in patients with dyslipidemia.